BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BioVisioN AG Spins Off New Enterprise With Peptide Vaccine Portfolio


10/19/2005 5:12:22 PM

HANNOVER, Germany, December 6 /PRNewswire/ -- Today the CEO of the Hannover, Germany based company BioVisioN AG, Dr. Sven Rohmann, announced the foundation of a new company, the ImVisioN GmbH, to develop therapies to cure allergic diseases. ImVisioN GmbH will be an independent company. The lead compound of the company will target cat allergy. The start of first clinical trials is anticipated already for next year.

"The basis of ImVisioN is a new immunization concept based on improved antigen presentation within the immune system. The vaccines are engineered protein molecules (Modulary-Antigen-Transporter molecules = MAT) constructed from three functionally different modules that allow the development of a therapeutic product portfolio", says Professor Horst Rose, COO of the new enterprise. Pre-clinical data generated in co-operation with the Swiss Institute of Allergy and Asthma Research (SIAF), a research institution associated with the University of Zurich, Switzerland, suggest a long term beneficial effect on allergic diseases such as hay fever, asthma and possibly on atopic eczema. "The mission of ImVisioN is to provide proof in man as quickly and thoroughly as possible", says Dr. Thomas Kundig, the head of the clinical programme. "The potential of ImVisioN results from the development of a portfolio of new pharmaceutical products based on the MAT concept suitable also for other indications, as for example particular infectious diseases".

The prevalence of allergic disorders has risen steadily over the past several decades. About one in every five adults and children suffer from allergies. The allergic rhinitis market has grown dramatically since the early 1990s. Between 2000 and 2003, annual sales of the major classes of prescription therapeutics used for the symptomatic treatment of this disease reached worldwide nearly US$5.9 billion.

Professor Reto Crameri, head of the Molecular Allergology Division at the SIAF in Davos (Switzerland) and main Inventor of MAT says: "I am pleased to see that we now have the chance to prove the new concept in clinical trials in order to help patients suffering from allergies."

Dr. Thomas Wagner from BioRegioN is also pleased about the new enterprise enabling product development from biotech research He counselled the ImVisioN Team during the course of formation.

About BioVisioN AG

BioVisioN AG specializes in the identification of disease-relevant peptides and proteins using its proprietary Peptidomics�± technologies in order to discover new diagnostic markers, or biomarkers and therapeutic leads and targets. Apart from research collaborations, BioVisioN provides access to its technology also in fee-for-service contracts as a Biological Research Organisation.

About SIAF

The SIAF founded in 1988 performs applied basic research in the field of allergies and asthma. The research is focused on discovery, production, structural and immunological characterization of allergenic molecules and on the study of the basic immunological mechanisms of allergic inflammations. The SIAF collaborates with clinics in Davos, Zurich and other international institutions and allows in collaboration with the University of Zurich the academic education in the area of allergy research.

This press release may contain forward-looking statements that, by their nature, involve certain risks, uncertainties and other factors that are, in some cases, beyond our control. The Company's results could differ materially from those expressed or implied in such statements. The forward- looking statements contained in this release speak only as of the date hereof, and we undertakes no obligation to correct or update any forward- looking statements, whether as a result of new information, future events or otherwise.

Press Contact: Prof. Horst Rose COO ImVisioN GmbH i.G. Feodor-Lynen-Str. 5 D-30625 Hannover Tel: +49-(0)511-538 896-0 Fax: +49-(0)511-538 896-66 Email : h.rose@biovision-discovery.dehttp://www.peptidomics.com/

BioVisioN AG

CONTACT: Prof. Horst Rose, COO, ImVisioN GmbH i.G., Feodor-Lynen-Str. 5,D-30625 Hannover, Tel: +49-(0)511-538 896-0, Fax:+49-(0)511-538 896-66, Email : h.rose@biovision-discovery.de,http://www.peptidomics.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES